Formycon AG (XTER:FYB) Change In Receivables : €-2.73 Mil (TTM As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Formycon AG Change In Receivables?

Formycon AG's change in receivables for the quarter that ended in Dec. 2024 was €8.65 Mil. It means Formycon AG's Accounts Receivable declined by €8.65 Mil from Jun. 2024 to Dec. 2024 .

Formycon AG's change in receivables for the fiscal year that ended in Dec. 2024 was €-2.73 Mil. It means Formycon AG's Accounts Receivable increased by €2.73 Mil from Dec. 2023 to Dec. 2024 .

Formycon AG's Accounts Receivable for the quarter that ended in Dec. 2024 was €23.69 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Formycon AG's Days Sales Outstanding for the six months ended in Dec. 2024 was 101.07.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Formycon AG's liquidation value for the six months ended in Dec. 2024 was €-250.13 Mil.

Formycon AG Change In Receivables Historical Data

The historical data trend for Formycon AG's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Change In Receivables Chart

Formycon AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

Get a 7-Day Free Trial

-4.46

3.08

-12.70

-2.73

Formycon AG Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Receivables	Get a 7-Day Free Trial															-0.33	-23.68	10.98	-11.38	8.65

Formycon AG Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-2.73 Mil.

Formycon AG (XTER:FYB) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Formycon AG's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	23.693	/	42.781	*	91
=	101.07

2. In Ben Graham's calculation of liquidation value, Formycon AG's accounts receivable are only considered to be worth 75% of book value:

Formycon AG's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	41.84	-	309.872	+	0.75 * 23.693	+	0.5 * 0.262
=	-250.13

Formycon AG Change In Receivables Related Terms

Thank you for viewing the detailed overview of Formycon AG's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Formycon AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (XTER:FYB) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

0W4N:UK

Address

Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152

Website

https://www.formycon.com

Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Executives

Dr. Nicola Mikulcik	Board of Directors
Dr. Stefan Glombitza	Board of Directors
Dr. Carsten Brockmeyer	Board of Directors
Dr. Nicolas Combé	Board of Directors

Formycon AG Headlines

No Headlines